• Hélène Pluchart, Julian Pinsolle, Julien Cohen, Gilbert R Ferretti, Pierrick Bedouch, Giaj Levra Matteo M Clinique Universitaire de Pneumologie, Pôle Thorax et Vaisseaux, CHU Grenoble Alpes, CS 10217, 38043, Grenoble, France., Anne-Claire Toffart, and Denis Moro-Sibilot.
• Pôle pharmacie, CHU Grenoble Alpes, CS 10217, 38043, Grenoble, France. Hpluchart@chu-grenoble.fr.
• J Med Case Rep. 2017 Jul 6; 11 (1): 183.

BackgroundNivolumab, a monoclonal antibody targeting the programmed death-1 receptor, is indicated in locally advanced or metastatic non-small cell lung cancer, with progression after platinum-based chemotherapy. Up-to-now, few data are available concerning brain activity of this treatment and concomitant use of corticosteroids.Case PresentationA 64-year-old caucasian man with a pulmonary adenocarcinoma associated with brain metastases received four courses of nivolumab in concomitance with a high dose of corticosteroids for his neurologic symptoms. He experienced a partial response in his brain and chest with an improvement in his general condition. Nivolumab was effective in shrinking symptomatic brain metastases, and metastases at other sites, in a patient with non-small cell lung cancer and first-line chemotherapy failure. The effect of nivolumab was obtained despite concomitant high-dose corticosteroid therapy. Combined nivolumab and high-dose corticosteroid therapy did not induce unexpected adverse events.ConclusionNivolumab and concomitant high-dose corticosteroid therapy was found to be efficient and well tolerated.

32 keywords...

hide…